CD19 and acute myeloid leukemia: We examined primary AML (PID20) engraftment kinetics after intravenous administration of 5 × 106 CD3/CD19 double-depleted PB cells in NSG mice through flow cytometry and immunohistochemistry analysis of the hematopoietic organ chimerism over the course of seven weeks.